Overview

Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program

Status:
Completed
Trial end date:
2016-05-06
Target enrollment:
0
Participant gender:
All
Summary
This study is multicentric, single-blind, and interventional with a randomization into two parallel arm, between a standard of care information and an additional information of the patient, with a 12 month follow up. The aim of this study is to evaluate the effectiveness of a personalized information program versus information provided from standard of care in patients taking Xarelto for Stroke Prevention in Atrial Fibrillation.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University Hospital, Montpellier
Treatments:
Rivaroxaban
Criteria
Inclusion Criteria:

- All patients treated with rivaroxaban chronically, (atrial fibrillation non-valvular
under current AMM) for less than one year whatever anti vitamin K treatment history

- Affiliate or beneficiary of a social security system.

- Patient who formulated its "does not oppose" to participate in this research

- Age higher than or equal to 18 years

Exclusion Criteria:

- Opposition to participation

- Patient don't understand french language

- Patient does not have responsibility for the management of treatment (treatment
administered by a nurse at home, or by caregivers)

- Tutorship or curatoship

- Law-protected patient

- Pregnant women or breast-feeding